Biologic agents in psoriasis

Simple item page
dc.contributor.buuauthorBaşkan, Emel Bülbül
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Dermatoloji Anabilim Dalı.tr_TR
dc.contributor.orcid0000-0002-0144-3263tr_TR
dc.contributor.researcheridAAH-1388-2021tr_TR
dc.contributor.scopusid6602518817tr_TR
dc.date.accessioned2024-02-27T07:30:37Z
dc.date.available2024-02-27T07:30:37Z
dc.date.issued2008-12
dc.description.abstractPsoriasis is a chronic, inflammatory disease affecting 1-3% of population. Advances in the pathogenesis of psoriasis and biotechnology have led to the development of targeted therapy named biologic agents. in this review, general information on biologic drugs are presented and literature on four biologic agents available in our country for moderate to severe plaque psoriasis has been summarized. Mechanisms of action, indications and dosage, results of clinical studies and safety profiles of each biologic agent are discussed.en_US
dc.identifier.citationBaşkan, E. B. (2008). "Biologic agents in psoriasis". Turkderm Deri Hastaliklari ve Frengi Arsivi, 40(Supplement 2), 42-50tr_TR
dc.identifier.endpage50tr_TR
dc.identifier.issn1019-214X
dc.identifier.issn1308-6294
dc.identifier.issueSupplement 2en_US
dc.identifier.scopus2-s2.0-63149181435tr_TR
dc.identifier.startpage42tr_TR
dc.identifier.urihttps://hdl.handle.net/11452/39986en_US
dc.identifier.volume42tr_TR
dc.identifier.wos000263169900006tr_TR
dc.indexed.pubmedPubMeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wos6602518817tr_TR
dc.language.isoenen_US
dc.publisherVakıf Gureba Eğitim ve Araştırma Hastanesi Kliniği
dc.relation.journalTurkderm Deri Hastaliklari ve Frengi Arsivitr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectDermatologyen_US
dc.subjectAdalimumaben_US
dc.subjectBiologicsen_US
dc.subjectEfalizumaben_US
dc.subjectEtanercepten_US
dc.subjectInfliximaben_US
dc.subjectPsoriasisen_US
dc.subjectChronic plaque psoriasisen_US
dc.subjectRandomized controlled-trialen_US
dc.subjectPatient-reported outcomesen_US
dc.subjectLong-termen_US
dc.subjecttreatmenten_US
dc.subjectPhase-IIIen_US
dc.subjectDouble-blinden_US
dc.subjectEfalizumab therapyen_US
dc.subjectRheumatoid-arthritisen_US
dc.subjectOpen-labelen_US
dc.subjectInfliximab monotherapyen_US
dc.subject.emtreeAdalimumaben_US
dc.subject.emtreeAlefacepten_US
dc.subject.emtreeAntipsoriasis agenten_US
dc.subject.emtreeEfalizumaben_US
dc.subject.emtreeEtanercepten_US
dc.subject.emtreeInfliximaben_US
dc.subject.emtreeTumor necrosis factor alpha inhibitoren_US
dc.subject.emtreeBiotechnologyen_US
dc.subject.emtreeClinical researchen_US
dc.subject.emtreeDisease severityen_US
dc.subject.emtreeDrug indicationen_US
dc.subject.emtreeDrug mechanismen_US
dc.subject.emtreeDrug safetyen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreePathogenesisen_US
dc.subject.emtreePsoriasisen_US
dc.subject.emtreeReviewen_US
dc.subject.scopusPustulosis Palmoplantaris; Ustekinumab; Etanercepten_US
dc.subject.wosDermatologyen_US
dc.titleBiologic agents in psoriasisen_US
dc.typeArticleen_US
dc.wos.quartile

Files

Collections

Web of Science